- Applications of imaging flow cytometry for FISH analysis and immunophenotyping of cells
- Technical aspects for immuno-flowFISH protocol development and optimization
- Clinical examples across a range of hematological malignancies
- Imaging flow cytometry users looking to improve their data quality and analysis
- Researchers in immunology, oncology, genomics, and measurable residual disease
- Anyone interested in flow cytometry or imaging flow cytometry
Imaging Flow Cytometry For Chromosomal Assessment In Hematological Malignancies
Free Virtual Webinar
June 12, 2024 | 3:30pm PDT | 6:30pm EDT
About The Event
The assessment of chromosomal abnormalities is a key component in the evaluation of blood cancers and is typically performed by karyotyping and fluorescence in situ hybridization (FISH). These cytogenetic techniques only analyze small numbers of cells (20 – 200) and are not “tumor-specific.” Hence, they are unsuitable for precise detection of genomic aberrations, low-level clones, or disease monitoring.
In this webinar, we will describe a new innovative approach we developed that resolves these limitations. The method called “Immuno-flowFISH”: immunophenotyping, flow cytometry, and FISH uses the Cytek® Amnis® ImageStream®X Mk II imaging flow cytometer for analysis. This integrated multi-parametric flow cytometric immunophenotyping and FISH method is performed on cells in suspension with one experiment and does not require any prior cell isolation or cell separation. Digital “in focus” photographic images of each cell are acquired enabling visualization of cellular morphology, antigens, and FISH chromosomal signals (“spots”). Specific cell populations are identified by their morphology and immunophenotypic characteristics and then analyzed for chromosomal makeup. Immuno‐flowFISH is suitable for the assessment of chromosomal defects in hemopoietic cells of lymphoid and myeloid lineage in blood or bone marrow, in acute and chronic blood cancer types. This method is more than 10,000 times more precise than current tests making it amenable to the detection of genomic defects at diagnosis as well as residual disease assessment. Immuno-flowFISH will lead to new discoveries in cancer biology and new prognosticators of disease and response.
Key topics discussed in this webinar will include:
Who should attend:
For Research Use Only. Not intended for use in diagnostic procedures.